Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The compan
2-Year Price History
Quarterly Financials & Projections
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Est | 2027-Q3 | 0.1 | -5.0 | -- | -5.1 | -- | -4.8 | -0.0 | -25.4 | -- | -- | -- | -- | -- |
| Est | 2027-Q2 | 0.1 | -4.8 | -- | -4.9 | -- | -4.5 | -0.0 | -20.6 | -- | -- | -- | -- | -- |
| Est | 2027-Q1 | 0.1 | -4.5 | -- | -4.6 | -- | -4.3 | -0.0 | -16.1 | -- | -- | -- | -- | -- |
| Est | 2026-Q4 | 0.1 | -4.0 | -- | -4.1 | -- | -3.8 | -0.0 | -11.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q3 | 0.1 | -3.5 | -- | -3.6 | -- | -3.3 | -0.0 | -8.1 | -- | -- | -- | -- | -- |
| Est | 2026-Q2 | 0.0 | -3.3 | -- | -3.4 | -- | -3.2 | -0.0 | -4.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q1 | 0.0 | -3.2 | -- | -3.2 | -- | -3.0 | -0.0 | -1.7 | -- | -- | -- | -- | -- |
| Act | 2026-Q1 | 0.0 | -3.5 | -3.5 | -3.5 | -3.1 | -3.1 | -0.0 | 4.1 | 0.5 | 47.8 | -341.4% | -- | -- |
| Est | 2025-Q4 | 0.0 | -3.0 | -- | -3.1 | -- | -2.9 | -0.0 | 1.3 | -- | -- | -- | -- | -- |
| Act | 2025-Q4 | 0.0 | -3.0 | -3.0 | -3.0 | -2.0 | -2.1 | -0.0 | 7.1 | 0.5 | 46.2 | -181.7% | -- | -- |
| Act | 2025-Q3 | 0.0 | -3.2 | -3.3 | -3.2 | -2.7 | -2.8 | -0.1 | 8.6 | 0.2 | 47.1 | -150.0% | -- | -- |
| Act | 2025-Q2 | 0.0 | -2.7 | -2.7 | -2.7 | -1.7 | -1.7 | -0.0 | 10.9 | 0.2 | 46.8 | -98.3% | -- | -- |
| Act | 2025-Q1 | 0.0 | -2.6 | -2.6 | -2.6 | -1.4 | -1.4 | -0.0 | 12.6 | 0.2 | 43.4 | -77.7% | -- | -- |
| Act | 2024-Q4 | 0.1 | -2.3 | -2.3 | -2.4 | -1.5 | -1.5 | -0.0 | 8.7 | 0.3 | 37.7 | -472.6% | -332.3x | -- |
| Act | 2024-Q3 | 0.0 | -3.0 | -3.0 | -3.0 | -2.2 | -2.2 | -0.0 | 6.9 | 0.3 | 37.6 | <-999% | -- | -- |
| Act | 2024-Q2 | 0.1 | -2.2 | -2.2 | -2.2 | -1.3 | -1.3 | -0.0 | 9.1 | 0.3 | 37.1 | -342.7% | -- | -- |
| Act | 2024-Q1 | 0.0 | -2.1 | -2.1 | -2.0 | -1.9 | -1.9 | -0.0 | 9.3 | 0.4 | 36.7 | -280.5% | -- | -- |
| Act | 2023-Q4 | 0.0 | -2.0 | -2.0 | -2.0 | -2.5 | -2.5 | -0.0 | 11.0 | 0.4 | 29.7 | -173.8% | -60.9x | -- |
| Act | 2023-Q3 | 0.0 | -2.3 | -2.4 | -2.4 | -1.5 | -1.5 | -0.0 | 7.6 | 0.4 | 28.8 | <-999% | -- | -- |
| Act | 2023-Q2 | 0.0 | -2.3 | -2.3 | -2.3 | -1.5 | -1.5 | -0.0 | 9.1 | 0.5 | 28.8 | <-999% | -- | -- |
| Act | 2023-Q1 | 0.0 | -2.2 | -2.2 | -2.2 | -1.6 | -1.6 | -0.0 | 10.7 | 0.1 | 28.8 | <-999% | -- | -- |
| Act | 2022-Q4 | 0.0 | -3.1 | -3.1 | -3.0 | -1.9 | -1.9 | -0.0 | 12.3 | 0.1 | 28.8 | <-999% | -- | -- |
| Act | 2022-Q3 | 0.0 | -2.9 | -2.9 | -3.1 | -2.9 | -2.9 | -0.0 | 14.3 | 0.1 | 28.8 | <-999% | -356.1x | -- |
| Act | 2022-Q2 | 0.0 | -3.2 | -3.3 | -3.2 | -2.7 | -2.7 | -0.0 | 17.3 | 0.2 | 28.8 | -323.0% | -- | -- |
| Act | 2022-Q1 | 0.1 | -3.8 | -3.8 | -3.8 | -4.8 | -4.8 | -0.0 | 20.1 | 0.2 | 28.8 | -230.1% | -- | -- |
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0.73 | — | -9666.4% | -13 | n/m | n/m | n/m | 217.2× |
| 2023 | 0.60 | -100.0% | — | -9 | n/m | n/m | n/m | — |
| 2024 | 2.12 | — | -5270.2% | -10 | n/m | n/m | n/m | 380.6× |
| 2025 | 1.94 | -76.8% | -27245.2% | -11 | n/m | n/m | n/m | >999× |
| TTM | 1.35 | -100.0% | — | -12 | 0.0× | 0.0× | 0.0× | — |
| 2026E | 1.35 | — | -87.2% | -0 | 0.0× | 0.0× | 0.0× | 0.0× |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
AI Analysis
LLM Evaluations
Entera Bio is a speculative, pre-revenue clinical-stage biotech burning ~$10-12M annually with only $8.6M in cash and no clear path to Phase 3 funding without massive dilution. While the oral teriparatide concept addresses a real unmet need (injection burden in osteoporosis), the company faces a multi-year funding gap: Phase 3 topline data isn't expected until H2 2028, requiring at least $50-80M in additional capital. With 47M shares outstanding and a 30M share ATM authorized, dilution will be extreme. The streamlined FDA pathway is genuinely positive, but the stock at ~$1.35/share already prices in significant option value. The 25%+ annual dilution rate, going concern qualification, zero revenue, and competitive threats from approved injectables (Forteo, Tymlos, Yorvipath) make this a poor risk/reward for fundamental investors. This is essentially a binary bet on clinical success years away, funded by continuous shareholder dilution.
Valuation & Metrics
Market Stats
TTM Financial Snapshot
DCF Fair Value Estimate
Forward Outlook & Risk
Short Interest
Options
| Strike | Call Bid/Ask | Call OI | Put Bid/Ask | Put OI |
|---|---|---|---|---|
| $1.00 | --/$3.30 | 0 | --/$3.00 | 0 |
| $2.00 | --/$4.50 | 0 | --/$3.80 | 0 |
| $3.00 | --/$0.20 | 70 | --/$4.70 | 0 |
| $4.00 | --/$4.40 | 0 | $0.45/$5.00 | 0 |
Forward Projections & Estimates
Employees
Cash Runway
Institutional Ownership
Headline & net flow
In Q1 2026 so far (quarter still filing), institutions are net sellers — bought 2.1% of float, sold 6.3%. 2 filers moved >1% of shares (0 buying, 2 selling).
Ownership composition
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC | $6.5M | $1.49 | +$0 | +$0 | -5.3% | $180M |
| RENAISSANCE TECHNOLOGIES LLC | $526K | $1.08 | +$406K | +$455K | +1.2% | $63.91B |
| Parkman Healthcare Partners LLC | $320K | $1.81 | +$15K | −$168K | -2.1% | $965M |
| CITADEL ADVISORS LLC | $273K | $1.17 | +$228K | +$273K | -0.4% | $138.22B |
| Seven Fleet Capital Management LP | $228K | $1.66 | +$78K | +$228K | +44.8% | $315M |
| MARSHALL WACE, LLP | $217K | $1.92 | −$479K | +$217K | +0.6% | $92.71B |
| NORTHERN TRUST CORPPassive | $163K | $2.12 | −$2K | −$58K | -0.2% | $755.34B |
| XTX Topco Ltd | $146K | $1.11 | +$134K | +$134K | -1.9% | $5.74B |
| Schonfeld Strategic Advisors LLC | $61K | $1.84 | −$601K | −$604K | +1.3% | $12.20B |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC | $53K | $1.90 | +$0 | +$0 | +0.1% | $4.93B |
| HighTower Advisors, LLC | $41K | $1.76 | −$7K | +$21K | -0.2% | $93.93B |
| JANE STREET GROUP, LLCMM | $37K | $1.93 | −$46K | +$37K | -0.1% | $92.10B |
| DIADEMA PARTNERS LP | $26K | $1.11 | +$26K | +$26K | +2.6% | $224M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $23K | $2.12 | +$0 | +$0 | +2.3% | $1.61T |
| Gem Investment Advisors, LLC | $21K | $1.94 | +$0 | +$21K | +5.7% | $102M |
| HRT FINANCIAL LP | $17K | $0.78 | −$12K | +$17K | -0.6% | $39.46B |
| Point72 Asset Management, L.P. | $14K | $1.70 | −$1.3M | −$3.0M | +0.9% | $54.88B |
| BANK OF AMERICA CORP /DE/ | $13K | $1.74 | −$3K | −$21K | -0.1% | $1.36T |
| PNC FINANCIAL SERVICES GROUP, INC. | $11K | $2.38 | +$0 | +$0 | +0.3% | $173.16B |
| JPMORGAN CHASE & CO | $7K | $1.12 | +$8K | +$7K | -0.2% | $1.47T |
Trading behavior
▸ Compare to holder-profile behavior (across all their stocks)
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 90.1%
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Analyst Coverage
| Quarter | Revenue | EBITDA | Net Inc | EPS | EPS Range | # Analysts |
|---|---|---|---|---|---|---|
| 2025 Q3 | 0M | 0M | -4M | $-0.09 | $-0.09 – $-0.09 | 1 |
| 2025 Q4 | 0M | 0M | -4M | $-0.09 | $-0.09 – $-0.09 | 1 |
| 2026 Q1 | 0M | 0M | -4M | $-0.08 | $-0.08 – $-0.08 | 1 |
| 2026 Q2 | 0M | 0M | -4M | $-0.08 | $-0.08 – $-0.08 | 1 |
| 2026 Q3 | 0M | 0M | -4M | $-0.08 | $-0.08 – $-0.08 | 1 |
| 2026 Q4 | 0M | 0M | -4M | $-0.09 | $-0.09 – $-0.09 | 1 |
| 2027 Q1 | 0M | 0M | -6M | $-0.13 | $-0.13 – $-0.13 | 1 |
| 2027 Q2 | 0M | 0M | -6M | $-0.13 | $-0.13 – $-0.13 | 1 |
| 2027 Q3 | 0M | 0M | -7M | $-0.15 | $-0.15 – $-0.15 | 1 |
| 2027 Q4 | 0M | 0M | -8M | $-0.16 | $-0.16 – $-0.16 | 1 |
Corporate
Executive Compensation (2022-2024)
Insider Trading (last 12mo)
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-09 | BUY | Germano Geno J | director | 20,000 | $1.30 | $26K | $52K |
| 2026-03-05 | BUY | Ellis Sean | director | 10,000 | $1.23 | $12K | $231K |
| 2026-02-10 | BUY | Germano Geno J | director | 20,000 | $1.49 | $30K | $0 |
| 2026-02-10 | BUY | Taitel Haya | director | 7,500 | $1.48 | $11K | $0 |
| 2026-02-09 | BUY | Ellis Sean | director | 18,000 | $1.24 | $22K | $221K |
| 2025-12-29 | BUY | Toledano Miranda Jayne | director, officer: Chief Executive Officer | 11,000 | $1.81 | $20K | $772K |
Order Flow (FINRA, ~3w lag)
Filing Risk Analysis
Filing Risk Scores
ENTERA BIO LTD.: Desperate Liquidity Measures and Regional Warfare Threaten Clinical Survival
Counter-Thesis
Counter-Thesis & Recent News
On March 4, 2026, Entera Bio submitted a streamlined Phase 3 protocol to the FDA for its lead candidate EB613 (oral teriparatide). The redesign uses total hip Bone Mineral Density (BMD) at 12 months as the primary endpoint—a shift enabled by the FDA's December 2025 qualification of BMD as a surrogate endpoint. This change is expected to accelerate the timeline for topline data to H2 2028, roughly one year earlier than previously projected. Additionally, the company is moving a single-tablet 'Next-Gen' formulation directly into Phase 3, simplifying future commercialization (Source: TipRanks, Stock Titan).
The bear thesis centers on a precarious cash runway and the 'pre-revenue' trap. As of late 2025, Entera reported approximately $16.6 million in cash, which is only expected to fund operations through mid-Q3 2026. With Phase 3 trials not expected to yield topline results until 2028, bears argue that massive dilutive financing is inevitable. Furthermore, technical indicators remain bearish, with the stock recently breaking its lower Bollinger Band and showing a negative MACD (Source: MarketBeat, Tickeron).
A primary red flag is the looming 'funding gap' between the current cash exhaustion date (mid-2026) and the start of dosing for Phase 3 (late 2026). This creates a high risk of a 'going concern' qualification or predatory financing. Additionally, the company reported $0 revenue in recent quarters, making it entirely dependent on capital markets for survival (Source: Intellectia.AI, FirstWord Pharma).
Entera faces intense competition from established injectable anabolic therapies like Forteo (Eli Lilly) and Tymlos (Radius Health). In the hypoparathyroidism space (EB612), they must contend with Ascendis Pharma’s recently approved Yorvipath and AstraZeneca’s acquisition of Amolyt Pharma, both of which target the same PTH-replacement market but with injectable formats that have already cleared regulatory hurdles (Source: TradingView, TipRanks).
Sentiment among clinical analysts and potential 'customers' (physicians/patients) remains highly positive regarding the delivery method. There is a documented 'injection burden' for the estimated 200 million women worldwide with osteoporosis; an oral anabolic option could significantly improve real-world adherence. Recent social media and insider tracking also noted a 11,000-share purchase by CEO Miranda Toledano in late 2025, signaling internal confidence that may counter negative retail sentiment (Source: Quiver Quantitative, TradingView).